Novozymes Biopharma and Almac have entered a collaboration to provide a combined service for drug targeting and pharmacokinetic improvements for drug development applications. The collaboration will employ Almac’s manufacturing assets and protein conjugation capability to link Novozymes’ Recombumin Flex technology to peptide and small molecule drugs in an effort to improve pharmacokinetics. The companies have begun collaborating with commercial partners and this process has been shown to improve...